To authorize the collection of supplemental payments to increase congressional investments in medical research, and for other purposes.
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill, To authorize the collection of supplemental payments to increase congressional investments in medical research, and for other purposes., changes federal law or congressional policy affecting health care providers and patients. The main policy domain is Healthcare, Finance, Government Operations.
Who Benefits and How
health care providers and patients may benefit from new authority, funding, eligibility, regulatory clarity, or reduced risk created by the bill.
Who Bears the Burden and How
federal implementing agencies, health care providers and patients may take on implementation duties, reporting obligations, compliance costs, or oversight responsibilities.
Key Provisions
- Section H91534951D01B4A958C2B91C1778D0DC7: 1. Short title This Act may be cited as the Medical Innovation Act of 2024.
- Section H7876C755CD2C4BB19791B3B13CFF2213: 2. Authority to assess and use supplemental payments to increase congressional investments in medical research Section 301 of the Public Health Service Act (42...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
This bill, To authorize the collection of supplemental payments to increase congressional investments in medical research, and for other purposes., changes federal law or congressional policy affecting health care providers and patients.
Key Policy Areas
Healthcare, Finance, Government Operations
Primary Purpose
This bill, To authorize the collection of supplemental payments to increase congressional investments in medical research, and for other purposes., changes federal law or congressional policy affecting health care providers and patients.
Policy Domains
Whole bill
Identified Gains
- health care providers and patients
Identified Costs
- federal implementing agencies
- health care providers and patients
Sponsors
Legislative Progress
IntroducedMs. Schakowsky (for herself, Ms. Castor of Florida, and Ms. …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_commission"
- → The commission identified in the operative section
- "secretary_of_health_and_human_services"
- → Secretary of Health and Human Services
Key Definitions
Terms defined in this bill
a settlement agreement (including a consent decree), and except as provided under clause (ii)— that is between an agency and a covered manufacturer
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology